BAXTER INTERNATIONAL INC (BAX) Fundamental Analysis & Valuation

NYSE:BAX • US0718131099

19.03 USD
0 (0%)
At close: Mar 4, 2026
19.0401 USD
+0.01 (+0.05%)
After Hours: 3/4/2026, 8:04:00 PM

This BAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, BAX scores 3 out of 10 in our fundamental rating. BAX was compared to 184 industry peers in the Health Care Equipment & Supplies industry. BAX may be in some trouble as it scores bad on both profitability and health. BAX is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. BAX Profitability Analysis

1.1 Basic Checks

  • In the past year BAX was profitable.
  • BAX had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: BAX reported negative net income in multiple years.
  • BAX had a positive operating cash flow in 4 of the past 5 years.
BAX Yearly Net Income VS EBIT VS OCF VS FCFBAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B

1.2 Ratios

  • BAX has a Return On Assets of -1.62%. This is in the better half of the industry: BAX outperforms 70.65% of its industry peers.
  • The Return On Equity of BAX (-4.71%) is better than 70.65% of its industry peers.
  • BAX has a better Return On Invested Capital (3.05%) than 70.65% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BAX is significantly below the industry average of 8.90%.
Industry RankSector Rank
ROA -1.62%
ROE -4.71%
ROIC 3.05%
ROA(3y)-0.58%
ROA(5y)1.52%
ROE(3y)-6.47%
ROE(5y)1.48%
ROIC(3y)3.5%
ROIC(5y)4.71%
BAX Yearly ROA, ROE, ROICBAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

  • BAX has a Operating Margin of 6.40%. This is in the better half of the industry: BAX outperforms 71.20% of its industry peers.
  • BAX's Operating Margin has declined in the last couple of years.
  • The Gross Margin of BAX (35.05%) is worse than 73.37% of its industry peers.
  • BAX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.4%
PM (TTM) N/A
GM 35.05%
OM growth 3Y-19.11%
OM growth 5Y-13.17%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.94%
GM growth 5Y-2.16%
BAX Yearly Profit, Operating, Gross MarginsBAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

3

2. BAX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BAX is destroying value.
  • BAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BAX Yearly Shares OutstandingBAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
BAX Yearly Total Debt VS Total AssetsBAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • An Altman-Z score of 2.22 indicates that BAX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of BAX (2.22) is better than 63.59% of its industry peers.
  • The Debt to FCF ratio of BAX is 38.94, which is on the high side as it means it would take BAX, 38.94 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of BAX (38.94) is better than 67.39% of its industry peers.
  • BAX has a Debt/Equity ratio of 1.21. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.21, BAX is doing worse than 77.17% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF 38.94
Altman-Z 2.22
ROIC/WACC0.42
WACC7.31%
BAX Yearly LT Debt VS Equity VS FCFBAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • BAX has a Current Ratio of 1.84. This is a normal value and indicates that BAX is financially healthy and should not expect problems in meeting its short term obligations.
  • BAX has a Current ratio of 1.84. This is in the lower half of the industry: BAX underperforms 66.30% of its industry peers.
  • A Quick Ratio of 1.18 indicates that BAX should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.18, BAX is not doing good in the industry: 68.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.18
BAX Yearly Current Assets VS Current LiabilitesBAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2

3. BAX Growth Analysis

3.1 Past

  • The earnings per share for BAX have decreased strongly by -16.24% in the last year.
  • Measured over the past years, BAX shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.98% on average per year.
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.03%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.95% on average over the next years.
  • Based on estimates for the next years, BAX will show a small growth in Revenue. The Revenue will grow by 2.22% on average per year.
EPS Next Y-0.01%
EPS Next 2Y3.92%
EPS Next 3Y5.38%
EPS Next 5Y6.95%
Revenue Next Year2.3%
Revenue Next 2Y2.29%
Revenue Next 3Y2.36%
Revenue Next 5Y2.22%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BAX Yearly Revenue VS EstimatesBAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5B 10B 15B
BAX Yearly EPS VS EstimatesBAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

6

4. BAX Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 8.38, the valuation of BAX can be described as very reasonable.
  • Based on the Price/Earnings ratio, BAX is valued cheaper than 96.74% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.03, BAX is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 8.38, the valuation of BAX can be described as very reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BAX indicates a rather cheap valuation: BAX is cheaper than 97.28% of the companies listed in the same industry.
  • BAX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.11.
Industry RankSector Rank
PE 8.38
Fwd PE 8.38
BAX Price Earnings VS Forward Price EarningsBAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 92.93% of the companies in the same industry are more expensive than BAX, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BAX indicates a somewhat cheap valuation: BAX is cheaper than 74.46% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 40.09
EV/EBITDA 10.38
BAX Per share dataBAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.92%
EPS Next 3Y5.38%

4

5. BAX Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.20%, BAX is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.20, BAX pays a better dividend. On top of this BAX pays more dividend than 90.22% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, BAX's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.2%

5.2 History

  • The dividend of BAX is nicely growing with an annual growth rate of 6.89%!
  • BAX has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)6.89%
Div Incr Years0
Div Non Decr Years0
BAX Yearly Dividends per shareBAX Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • The earnings of BAX are negative and hence is the payout ratio. BAX will probably not be able to sustain this dividend level.
  • BAX's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP-119.65%
EPS Next 2Y3.92%
EPS Next 3Y5.38%
BAX Yearly Income VS Free CF VS DividendBAX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B

BAX Fundamentals: All Metrics, Ratios and Statistics

BAXTER INTERNATIONAL INC

NYSE:BAX (3/4/2026, 8:04:00 PM)

After market: 19.0401 +0.01 (+0.05%)

19.03

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners102.74%
Inst Owner Change7.02%
Ins Owners0.28%
Ins Owner Change11.63%
Market Cap9.78B
Revenue(TTM)N/A
Net Income(TTM)-341.00M
Analysts55.2
Price Target22.21 (16.71%)
Short Float %8.33%
Short Ratio4.43
Dividend
Industry RankSector Rank
Dividend Yield 0.2%
Yearly Dividend1.16
Dividend Growth(5Y)6.89%
DP-119.65%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-27
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.96%
Min EPS beat(2)-4.25%
Max EPS beat(2)14.16%
EPS beat(4)3
Avg EPS beat(4)8.34%
Min EPS beat(4)-4.25%
Max EPS beat(4)14.16%
EPS beat(8)7
Avg EPS beat(8)5.47%
EPS beat(12)9
Avg EPS beat(12)3.78%
EPS beat(16)11
Avg EPS beat(16)3.66%
Revenue beat(2)0
Avg Revenue beat(2)-1.91%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)-1.44%
Revenue beat(4)2
Avg Revenue beat(4)-0.36%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)1.93%
Revenue beat(8)5
Avg Revenue beat(8)-0.06%
Revenue beat(12)6
Avg Revenue beat(12)-0.48%
Revenue beat(16)6
Avg Revenue beat(16)-2.41%
PT rev (1m)-6.44%
PT rev (3m)-12.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.52%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-0.45%
Valuation
Industry RankSector Rank
PE 8.38
Fwd PE 8.38
P/S 0.89
P/FCF 40.09
P/OCF 13.06
P/B 1.35
P/tB N/A
EV/EBITDA 10.38
EPS(TTM)2.27
EY11.93%
EPS(NY)2.27
Fwd EY11.93%
FCF(TTM)0.47
FCFY2.49%
OCF(TTM)1.46
OCFY7.66%
SpS21.44
BVpS14.09
TBVpS-5.77
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.82
Profitability
Industry RankSector Rank
ROA -1.62%
ROE -4.71%
ROCE 4.08%
ROIC 3.05%
ROICexc 3.39%
ROICexgc 9.84%
OM 6.4%
PM (TTM) N/A
GM 35.05%
FCFM 2.21%
ROA(3y)-0.58%
ROA(5y)1.52%
ROE(3y)-6.47%
ROE(5y)1.48%
ROIC(3y)3.5%
ROIC(5y)4.71%
ROICexc(3y)3.9%
ROICexc(5y)5.53%
ROICexgc(3y)10.35%
ROICexgc(5y)12.85%
ROCE(3y)4.85%
ROCE(5y)6.42%
ROICexgc growth 3Y-24.28%
ROICexgc growth 5Y-17.95%
ROICexc growth 3Y-15.78%
ROICexc growth 5Y-22.54%
OM growth 3Y-19.11%
OM growth 5Y-13.17%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.94%
GM growth 5Y-2.16%
F-Score3
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF 38.94
Debt/EBITDA 5.17
Cap/Depr 51.22%
Cap/Sales 4.58%
Interest Coverage 250
Cash Conversion 44.27%
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.18
Altman-Z 2.22
F-Score3
WACC7.31%
ROIC/WACC0.42
Cap/Depr(3y)49.31%
Cap/Depr(5y)63.51%
Cap/Sales(3y)5.12%
Cap/Sales(5y)5.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
EPS Next Y-0.01%
EPS Next 2Y3.92%
EPS Next 3Y5.38%
EPS Next 5Y6.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.03%
Revenue Next Year2.3%
Revenue Next 2Y2.29%
Revenue Next 3Y2.36%
Revenue Next 5Y2.22%
EBIT growth 1Y-43.57%
EBIT growth 3Y-23.92%
EBIT growth 5Y-14.31%
EBIT Next Year53.79%
EBIT Next 3Y15.53%
EBIT Next 5Y17.33%
FCF growth 1Y-73.82%
FCF growth 3Y-27.1%
FCF growth 5Y-16.46%
OCF growth 1Y-54.16%
OCF growth 3Y-22.88%
OCF growth 5Y-13.5%

BAXTER INTERNATIONAL INC / BAX FAQ

What is the fundamental rating for BAX stock?

ChartMill assigns a fundamental rating of 3 / 10 to BAX.


Can you provide the valuation status for BAXTER INTERNATIONAL INC?

ChartMill assigns a valuation rating of 6 / 10 to BAXTER INTERNATIONAL INC (BAX). This can be considered as Fairly Valued.


What is the profitability of BAX stock?

BAXTER INTERNATIONAL INC (BAX) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for BAX stock?

The Earnings per Share (EPS) of BAXTER INTERNATIONAL INC (BAX) is expected to decline by -0.01% in the next year.


How sustainable is the dividend of BAXTER INTERNATIONAL INC (BAX) stock?

The dividend rating of BAXTER INTERNATIONAL INC (BAX) is 4 / 10 and the dividend payout ratio is -119.65%.